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Introduction Abstracts
The following abstract is part of an ongoing series Abstract. Anticoagulants (heparin, low molecular
weight heparin and oral anticoagulants) for inter-of articles produced by the Cochrane Collaborative
Review Group on Peripheral Vascular Diseases, which mittent claudication.
B. Cosmi, E. Conti, and S. Coccheriis part of the Cochrane Collaboration. The review is
published in full on The Cochrane Library, a quarterly Date of most recent substantive amendment: 27 February
2001electronic journal available on CD-ROM and via the
Internet. The electronic format allows Cochrane re-
views to accommodate new data as they become avail-
able, making the library a consistently up-to-date
Backgroundsource of information over time.
The abstracts appearing on the Cochrane Library
Anticoagulant treatment for intermittent claudicationare now presented in a different, simpler, less scientific
might improve functional capacity, and prevent acuteformat than the abstracts usually presented here to
cardiovascular complications caused by peripheral ob-permit greater accessibility to the public. However,
structive arterial disease.the substance of both versions is the same. Cochrane
reviews are now indexed on MedLine.
If you are interested in writing a Cochrane review
or contributing to the activities of the Cochrane Peri- Objectives
pheral Vascular Diseases Group please contact:
To assess the effects of anticoagulant drugs (heparin,
Professor F. G. R. Fowkes low molecular weight heparin (LMWH) and oral anti-
Cochrane Collaborative Review Group on coagulants) in patients with intermittent claudication
Peripheral Vascular Diseases (Fontaine stage II) in terms of improving walking
Public Health Sciences capacity (pain-free walking distance or absolute walk-
University of Edinburgh ing distance), mortality, cardiovascular events, ankle/
Teviot Place brachial pressure index, progression to surgery, am-
Edinburgh EH8 9AG putation-free survival and side effects of these drugs.
Tel. +44 (0) 131 650 3220
Fax. +44 (0) 131 650 6904
Search strategyAny comments or criticisms on Cochrane reviews/
abstracts should be made through the comments/
Randomised trials of anticoagulants for intermittentcriticisms facility on the Cochrane Library, or by con-
claudication were sought using the search strategytacting the group at the above address.
described by the Cochrane Peripheral Vascular Dis-
eases Review Group. Additional trials were sought
through: reference lists resulting from this search;
recent conference proceedings; contact with authors
1078–5884/01/110403+02 $35.00/0  2001 Harcourt Publishers Ltd.
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of published trials and pharmaceutical companies pro- ing distance or maximum walking distance at the end
of treatment. There were no data to indicate thatducing anticoagulants.
LMWHs benefit walking distance. Revascularisation
or amputation-free survival rates were reported in
one study only with a five-year follow-up. No study
Selection criteria reported a significant effect on overall mortality or
cardiovascular events and the pooled odds ratios wereAll randomised trials of anticoagulants used to treat not significant for these outcomes either. Major andpatients with intermittent claudication. minor bleeding events were significantly more fre-
quent in the group treated with oral anticoagulants
compared to control, with a non-significant increase
in fatal bleeding events. No major bleeding eventsData collection and analysis
were reported in the study evaluating heparin, while
a non-significant increase in minor bleeding eventsThirteen trials were initially considered eligible for
inclusion in the review. Two studies evaluated oral was reported.
anticoagulants, five evaluated standard heparin, and
six evaluated LMWHs. Only three studies (two eval-
uating oral anticoagulants, one evaluating heparin)
met the high quality methodological inclusion criteria
and were included in the primary analysis. Four other
studies were included in the sensitivity analysis. The
Reviewers’ conclusionsreviewers extracted the data independently.
No benefit of heparin, LMWHs or oral anticoagulants
has been established for intermittent claudication. An
increased risk of major bleeding events has been ob-Main results
served especially with oral anticoagulants. The use of
anticoagulants for intermittent claudication cannot beNo significant difference was observed between hep-
arin treatment and control groups for pain-free walk- recommended at this stage.
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